文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

Ⅰ和Ⅱ期子宫内膜癌辅助阴道近距离放疗30 Gy分6次方案的毒性与疗效

Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-08-12

本研究评估247例Ⅰ和Ⅱ期子宫内膜癌患者术后辅助高剂量率阴道残端近距离放疗(30 Gy分6次、每周2次)的结局与毒性。中位随访5.8年,5年局部复发率5%、区域复发率5%、远处转移率7%,5年总生存率91%、无病生存率83%;无3~5级毒性。

要点

  • 深肌层浸润可预测局部复发(P = .002)。
  • 5年局部复发、区域复发、远处转移率分别为5%、5%、7%。
  • 最常见1级毒性为阴道狭窄21%、慢性尿频13%、尿失禁13%、急性乏力11%、尿频11%。

核心结论

  • 辅助阴道近距离放疗30 Gy分6次方案毒性低、无≥3级不良事件,局部控制率与其他已发表的不同分次方案相当。

研究设计与样本

  • 回顾性评估1992年至2018年间接受手术分期及辅助高剂量率阴道残端近距离放疗(不作外照射)的247例国际妇产科联盟Ⅰ和Ⅱ期子宫内膜癌患者。

主要发现

  • 中位随访5.8年(范围0.1~24.7年),52%为ⅠA期、37%为ⅠB期、11%为Ⅱ期。
  • 深肌层浸润可预测局部复发(P = .002)。
  • 5年局部复发率5%、区域复发率5%、远处转移率7%,5年总生存率91%、无病生存率83%。
  • 最常见1级毒性为急性乏力(粗率11%)、尿频(11%)、慢性(>6个月)尿频(13%)、尿失禁(13%)、阴道狭窄(21%)。
  • 2级毒性少见(均<5%),无3~5级毒性。

关键数值与推荐

  • 所有患者接受30 Gy分6次照射阴道上三分之一,处方深度5 mm,每周2次。
  • 毒性在每个随访点前瞻性采集,复发率和生存率回顾性评估。

临床怎么用

  • 本研究中心对Ⅰ和Ⅱ期子宫内膜癌术后患者采用30 Gy分6次、每周2次的阴道残端近距离放疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate outcomes and toxicity in patients with endometrial cancer per our institutional adjuvant vaginal cuff brachytherapy (VBT) fractionation scheme. METHODS AND MATERIALS: We identified women with International Federation of Gynecology and Oncology stages I and II endometrial cancer who underwent surgical staging and adjuvant high-dose-rate VBT without external beam radiation. All patients received 30 Gy in 6 fractions to the upper one-third of the vagina, prescribed to a depth of 5 mm and delivered twice weekly. Toxicities were prospectively elicited at each follow up, and rates of recurrence and survival were retrospectively assessed. RESULTS: We identified 247 eligible patients treated between 1992 and 2018 with a median follow up of 5.8 years (range, 0.1-24.7 years). Most patients had stage I disease (52% stage IA; 37% stage IB), and 11% of patients were stage II. Deep myometrial invasion was predictive of local recurrence (P = .002). The 5-year rates of local recurrence, regional recurrence, and distant metastases were 5%, 5%, and 7%, respectively. Five-year overall and disease-free survival were 91% and 83%, respectively. The most common grade 1 toxicities were acute fatigue (11% crude rate), urinary frequency (11%), chronic (>6 months) urinary frequency (13%), urinary incontinence (13%), and vaginal stenosis (21%). There were few grade 2 toxicities (all <5%) and no grade 3 to 5 toxicities. CONCLUSIONS: The adjuvant VBT fractionation scheme of 30 Gy in 6 fractions results in low rates of toxicity, with no grade ≥3 adverse events, and local control rates comparable with those from other published series using different fractionation schemes.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Arden JD, Dokter J, Almahariq MF, et al. Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial Cancer. Adv Radiat Oncol. 2021. PMID: 34934859. doi:10.1016/j.adro.2021.100773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。